Investors Attention Alert: Sutro Biopharma, Inc. (NASDAQ-STRO)

Sutro Biopharma, Inc. (NASDAQ-STRO) stock identified change of 39.65% away from 52-week low price and recently located move of -25.35% off 52-week high price. A look on the firm performance, its monthly performance is 17.18% and a quarterly performance of 5.14%. The stock price is moving up from its 20 days moving average with 4.53% and isolated positively from 50 days moving average with 9.24%.

Sutro Biopharma, Inc. (STRO) recently stated its financial results for the year ended December 31, 2018.

Full Year 2018 Financial Highlights

Cash, Cash Equivalents and Marketable Securities

As of December 31, 2018, Sutro had cash, cash equivalents and marketable securities of $204.5M. 


Revenue was $38.4M for the year ended December 31, 2018, which included alliance revenue of $32.4M recognized primarily from Celgene, Merck and EMD Serono, in addition to other revenue of $6.0M. During the third and fourth quarters of 2018, Sutro began recording revenue from Merck, primarily from the $60.0M upfront payment received by Sutro under the July 2018 alliance and licensing contract, which revenue will be recognized over multiple years. Future alliance revenue from Celgene, Merck and EMD Serono, and from any future alliance partners, will fluctuate as a result of the amount and timing of revenue recognition of upfront, milestones and other alliance contract payments.   

Operating Expenses

Total operating expenses for the year ended December 31, 2018, were $75.6Mcontrast with $71.0M for the same period in 2017, including non-cash stock-based compensation of $2.9M and $1.4M, and depreciation and amortization expense of $4.5M and $5.0M, in the year 2018 and 2017, respectively.  Total operating expenses for the year 2018 were comprised of research and development expenses of $54.3M and general and administrative expenses of $21.4M, with both expense types predictable to raise in 2019 as Sutro’s internal product candidates advance in clinical development and additional general and administrative expenses are incurred as a public company following its IPO that closed on October 1, 2018.   

Net Loss Per Share Calculation

Sutro financial statements following September 30, 2018, including share and per share amounts, give effect to ordinary stock shares issued in the IPO and the Merck concurrent private placement, and ordinary stock from the conversions of Sutro’s before outstanding redeemable convertible preferred stock, as these transactions were completed on October 1, 2018.  

Sutro Biopharma, Inc. (STRO) moved with change of -0.17% to $11.87 with the total traded volume of 33,835 shares in recent session versus to an average volume of 27,412. After opening the first trading session at $11.98, it registered a day’s high of $12.16 and touched a day’s low of $11.57. (STRO) has price-to-cash ratio of 1.64 and price to sale ratio of 6.76.

Leave a Reply

Your email address will not be published. Required fields are marked *